Table 1.
Baseline patient characteristics.
| Occluder systems | Total | P-value | ||
|---|---|---|---|---|
| SOPT | DODT | |||
| N | 60 | 89 | 149 | |
| Female | 23 (38.3%) | 28 (31.5%) | 51 (34.2%) | 0.49 |
| Age (y) | 74.5 (7.89) | 75.7 (8.09) | 75.2 (8.00) | 0.46 |
| BMI (kg/m²) | 26.9 (4.93) | 26.9 (4.99) | 26.9 (4.95) | 0.99 |
| Arterial hypertension | 53 (88.3%) | 74 (83.1%) | 127 (85.2%) | 0.52 |
| Coronary artery disease | 32 (53.3%) | 49 (55.1%) | 81 (54.4%) | 0.97 |
| Peripheral arterial disease | 9 (15.0%) | 18 (20.2%) | 27 (18.1%) | 0.55 |
| Hyperlipidemia | 22 (36.7%) | 40 (44.9%) | 62 (41.6%) | 0.40 |
| Diabetes | 23 (38.3%) | 26 (29.2%) | 49 (32.9%) | 0.33 |
| Obesity | 19 (31.7%) | 24 (27.0%) | 43 (28.9%) | 0.66 |
| Chronic kidney disease | 6 (10.0%) | 13 (14.6%) | 19 (12.8%) | 0.56 |
| Dialysis | 5 (8.3%) | 7 (7.9%) | 12 (8.1%) | 1 |
| Liver disease | 3 (21.4%) | 7 (38.9%) | 10 (31.3%) | 0.50 |
| Atrial fibrillation | ||||
| Paroxysmal | 22 (36.7%) | 38 (42.7%) | 60 (40.3%) | 0.57 |
| Persistent | 29 (48.3%) | 37 (41.6%) | 66 (44.3%) | 0.52 |
| Permanent | 9 (15.0%) | 14 (15.7%) | 23 (15.4%) | 1 |
| CHA2DS2-VASc | 5.00 [2.00–8.00] | 5.00 [2.00–8.00] | 5.00 [2.00–8.00] | 0.60 |
| HAS-BLED | 3.00 [2.00–6.00] | 3.00 [0–7.00] | 3.00 [0–7.00] | 0.80 |
| History of bleeding | 49 (81.7%) | 78 (87.6%) | 127 (85.2%) | 0.44 |
| Gastrointestinal bleeding | 23 (46.9%) | 46 (59.0%) | 69 (54.3%) | 0.25 |
| Intracranial bleeding | 12 (24.5%) | 15 (19.2%) | 27 (21.3%) | 0.63 |
| Unstable INR | 9 (15.0%) | 15 (16.9%) | 24 (16.1%) | 0.94 |
| Poor mobility | 5 (10.2%) | 2 (2.6%) | 7 (5.5%) | 0.15 |
| Other indications for LAAO | 32 (58.2%) | 46 (54.8%) | 78 (56.1%) | 0.82 |
| Anticoagulation | ||||
| VKA | 8 (14.0%) | 9 (10.5%) | 17 (11.9%) | 0.70 |
| NOAC | 23 (40.4%) | 44 (51.2%) | 67 (46.9%) | 0.27 |
| Heparin (+derivatives) | 5 (8.8%) | 17 (19.8%) | 22 (15.4%) | 0.12 |
| ASA ± P2Y12 antagonist | 17 (29.8%) | 19 (22.1%) | 36 (25.2%) | 0.40 |
| No anticoagulation | 3 (5.3%) | 1 (1.2%) | 4 (2.8%) | 0.35 |
Values are displayed as frequencies (%), mean (standard deviation), or median [interquartile range].
VKA, vitamin K antagonists.